12:00 AM
Sep 27, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

HspE7 (SGN-00101): Completed Phase I study

StressGen Biotechnologies Corp. (TSE:SSB), Victoria, B.C.
Product: HspE7 ( SGN-00101)
Business: Cancer
Therapeutic category: Immune stimulation...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >